Entity

Time filter

Source Type

Santa Ana, CA, United States

Aliakbari F.,Tehran University of Medical Sciences | Gilani M.A.S.,Tehran University of Medical Sciences | Gilani M.A.S.,Royan Institute for Stem Cell Biology and Technology | Amidi F.,Tehran University of Medical Sciences | And 5 more authors.
Cellular Reprogramming | Year: 2016

Cryopreservation of spermatogonial stem cells (SSCs) is an applicable method for young males seeking fertility preservation before starting a treatment. It increases reactive oxygen species (ROS) formation and oxidative stress, which damages cellular structures. In this study, we added two antioxidants, catalase and α-tocopherol (α-TCP), to the basic freezing medium to evaluate their effects on the efficiency of SSCs. SSCs were isolated from testes of 3- to 6-day-old male mice using enzymatic digestion. The enrichment of isolated cells was evaluated by flow cytometry and Stra8 antibody. Catalase (40 μg/mL), or α-TCP (200 μg/mL) was added to the basic freezing medium. The cell viability was evaluated by the methylthiazoltetrazolium (MTT) assay. After thawing, cells were cultured for 1 month, and the expression pattern of specific genes of SSCs and the ability of the cells to restore spermatogenesis were used to determine the efficiency of the cryopreservation method. The survival rate of the frozen cells in the presence of catalase or α-TCP was significantly higher than the control group (p < 0.05). The number of colonies and their diameter measured after 1 month were significantly higher in the antioxidant groups than in the control group (p < 0.05). Gene expression and resumption of spermatogenesis also followed the same pattern. Thus, adding antioxidants to the basic freezing medium can be helpful in increasing the quality and viability of SSCs after cryopreservation. This new approach to stem cells cryopreservation can also be a promising strategy for fertility preservation in patients who suffer from malignancy. © Copyright 2016, Mary Ann Liebert, Inc.


Supronowicz P.,Circle Biologics | Gill E.,Circle Biologics | Trujillo A.,Circle Biologics | Thula T.,Circle Biologics | And 3 more authors.
Tissue Engineering - Part A | Year: 2011

Background: Tissue engineering of new bone relies on the combination and application of osteoconductive, osteoinductive, and osteogenic elements. Natural scaffolds, such as demineralized bone matrix (DBM), contain collagenous networks with growth factors such as bone morphogenetic protein-2. Stem cells from readily available sources, including discarded adipose tissue, have the propensity to differentiate into bone. The present study examines a multi-component technique consisting of a novel side population of adipose stem cells cultured on DBM for tissue engineering applications. Methods: Adipose-derived side population stem cells were cultured on DBM for up to 14 days. Cell proliferation, alkaline phosphatase activity, extracellular matrix protein production, and calcium-containing mineral deposit formation were assayed. Ectopic bone formation in a rat model was also evaluated. Results: Side population stem cells attached to and proliferated on DBM while generating markers of new bone formation. When these cell/substrate composites were implanted into an ectopic model, newly formed bone was 30% greater than that of DBM alone. Conclusions: Novel populations of adipose-derived stem cells cultured on DBM compose a system that develops new bone matrix in vitro and in vivo. This strategy provides a novel approach using naturally occurring materials for bone repair in tissue engineering applications. © Mary Ann Liebert, Inc. 2011.


Trademark
PrimeGen Biotech LLC | Date: 2009-07-14

Modified stem cells suitable for use as pharmaceutical biologicals in the treatment and prevention and disease and injury to humans and non-human animals.


Trademark
PrimeGen Biotech LLC | Date: 2005-02-10

Modified stem cells suitable for use as pharmaceutical biologicals in the treatment and prevention and disease and injury to humans and non-human animals.


Trademark
PrimeGen Biotech LLC | Date: 2005-07-20

Modified stem cells suitable for use as pharmaceutical biologicals in the treatment and prevention and disease and injury to humans and non-human animals. Collection and preservation of modified stem cells suitable for use as pharmaceutical biologicals in the treatment and prevention of disease and injury to humans and non-human animals.

Discover hidden collaborations